News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Array BioPharma, Inc. (ARRY) Announces Clinical Data Presentations At The 2014 American Society of Clinical Oncology Annual Meeting


5/14/2014 6:45:14 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BOULDER, Colo., May 14, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced presentations on its MEK inhibitors, binimetinib (MEK162) (co-developing with Novartis) and selumetinib (licensed to AstraZeneca) at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 30 June 3, 2014 in Chicago, Illinois. Both MEK inhibitors are advancing in Phase 3 or pivotal trials: binimetinib is being evaluated in NRAS- and BRAF-mutant melanoma and low-grade serous ovarian cancer. In addition, selumetinib is being evaluated in non-small cell lung cancer, uveal melanoma and thyroid cancer.

Array BioPharma

Ron Squarer, Chief Executive Officer of Array, noted, "We are encouraged to see six ASCO abstracts reporting clinical results for our two partnered MEK programs, while steady progress continues across the pivotal trials for these programs."

The following is a summary of the presentations that will be given at ASCO:

Oral Presentation



Title:

A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity (Abstract #9009)

Presenter:

Jeffrey Alan Sosman, MD

Date:

Sunday, June 1, 8:24 8:36 a.m. CDT (Oral Presentation)


Poster Presentations



Title:

A phase 1b dose escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors (Abstract #9051)

Presenter:

Dejan Juric, MD

Date:

Saturday, May 31, 8 11:45 p.m. CDT



Title:

Effect of the BRAF inhibitor LGX818 on endoplasmic reticulum stress and sensitivity of NRAS-mutant melanoma cells to the MEK inhibitor binimetinib (Abstract #9062)

Presenter:

Friedegund Elke Meier, Prof. Dr. med.

Date:

Saturday, May 31, 8 11:45 p.m. CDT



Title:

ABC-04: A phase 1b trial of cisplatin, gemcitabine and selumetinib in patients with advanced biliary tract cancers (Abstract #4090)

Presenter:

John A. Bridgewater, MD

Date:

Saturday, May 31, 8 11:45 a.m. CDT



Title:

Phenformin combines with selumetinib in targeting KRAS mutant non-small cell lung cancer cells with alternative LKB1 status (Abstract #2589)

Presenter:

Jun Zhang, MD, Ph.D.

Date:

Sunday, June 1, 8 11:45 a.m. CDT



Title:

The Role of MEK inhibition in Neuroblastoma Tumor Cells (Abstract #10068)

Presenter:

Avinash Gupta, MBBS BSc MRCP

Date:

Monday, June 2, 8 11:45 a.m. CDT



Title:

Phase I Study of the MEK1/2 inhibitor selumetinib (AZD6244 hydrogen sulfate) in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs) (Abstract #10018)

Presenter:

Brigitte C. Widemann, MD

Date:

Monday, June 2, 8 a.m. 11:45 a.m. CDT



Title:

A phase 1 study of AZD6244 in children with recurrent or refractory low-grade gliomas: A Pediatric Brain Tumor Consortium report (Abstract #10065)

Presenter:

Anuradha Banerjee, MD

Date:

Monday, June 2, 8 a.m. 11:45 a.m. CDT



Title:

NCI #8412: A randomized phase II trial of AZD6244 alone and AZD6244 plus temsirolimus for soft-tissue sarcomas (Abstract #10526)

Presenter:

Zeynep Eroglu, MD

Date:

Tuesday, June 3, 8 11:00 a.m. CDT

Trials in Progress posters will also showcase the trial designs for the binimetinib trials in low-grade serous ovarian cancer (MILO) and NRAS mutant melanoma (NEMO).

ASCO's embargo for abstracts in this release will lift on Wednesday, May 14 at 6:00 p.m. EDT. All abstracts can be accessed through the ASCO website, http://abstract.asco.org/. After the presentations and posters are public, they will be available as PDFs on Array's website at www.arraybiopharma.com.

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Seven Phase 3 or pivotal studies are already in progress, or are planned to begin this year. These programs include the wholly-owned hematology drug, filanesib (ARRY-520) for multiple myeloma and two partnered cancer drugs, selumetinib (AstraZeneca) and binimetinib (MEK162 / Novartis). For more information on Array, please go to www.arraybiopharma.com.

CONTACT:

Tricia Haugeto


(303) 386-1193


thaugeto@arraybiopharma.com

Logo - http://photos.prnewswire.com/prnh/20121029/LA02195LOGO

SOURCE Array BioPharma



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES